|
Infant cardiopulmonary bypass (Cardiopulmonary bypass, CPB) pulmonary complications after surgery there is always a higher incidence of pulmonary edema, atelectasis, and even respiratory distress syndrome often encountered in clinical practice, but also cause cardiac pulmonary complications surgery one of the main failure and even death, but the immature lung protection during cardiopulmonary bypass little research. The purpose of the experiment is to establish a cardiopulmonary immature lung injury in animal models to understand the mechanism of lung injury in immature CPB explore lung fluid and additives to protect the protective effect of pulmonary perfusion. Materials and Methods The experiment used 56 healthy mongrel puppies, age is 28 ~ 32d, male or female, weight 1.0 ~ 2.0kg, fasting six hours before the experiment. Randomly divided into seven groups: ① operated control group; ② CPB; ③ normal control group; ④ CPB control group; ⑤ simple LPD perfusion group; ⑥ L-Arg infusion group; ⑦ Salvia infusion group; n = 8 animals. Control group, intravenous heparin after thoracotomy and maintain 120min. CPB group in the connecting pipe, pre-charge, after the right carotid artery retrograde perfusion tube inserted into an artery and right atrial venous drainage tube insertion method to establish cardiopulmonary bypass (CPB), cooling, blocking the aorta, pulmonary artery and stopped breathing, aortic Improved root infusion 4 ℃ St.Thomas Ⅱ solution after 60min in occlusion, open the main pulmonary artery, rewarming, cardiac resuscitation, parallel-flow shutdown after 60min. Pure potassium dextran (Low-potassium-dextran, LPD) perfusion during extracorporeal circulation group, pulmonary lung protection LPD remote continuous perfusion fluid flow 150ml/Kg/h, pressure 14 ~ 16mmHg, until the Lord, pulmonary artery open. L-arginine (L-Arginine, L-Arg) infusion group and Salvia (Salvia) perfusion group is L-Arg and Salvia LPD solution were added after pulmonary perfusion. The groups were shut down after the lung tissue specimens. Determination of pulmonary vein PaO 2 / FiO 2 , bronchoalveolar lavage fluid (Bronchial Alveolar Lavage Fluid BALF) in lung surfactant (Pulmonary Surfactant PS) level, a lung tissue NO (Nitric Oxide, NO), malondialdehyde (Malonyldialdehyde, MDA) content and myeloperoxidase (Myeloperoxidase, MPO) activity in lung tissue wet to dry weight ratio (W / D) and pulmonary vascular permeability (EB intensity value), the production of light microscopy, electron microscopy specimens observed histological and ultrastructural changes.
|